[
    " receptor \u03b1<sub>2</sub>\u03b2 and m but which are not antagonists of the adrenergic receptor am- In another variation, compounds that bind to and are antagonists of the adrenergic receptor a<sub>2</sub>A are provided, wherein the compounds also bind to and are antagonists of the adrenergic receptors am, but which are not antagonists of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 or a . Such compounds, when administered in the methods detailed herein, may be administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. </p> [0100] The second agent that reduces, or is expected to reduce, blood pressure in an individual may be a diuretic, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist, a beta blocker, a calcium channel blocker, or any combination thereof. In one variation, the second agent that reduces, or is expected to reduce, blood pressure in an individual is a compound that binds to and is an antagonist of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 but which is not an antagonist of the adrenergic receptor \u03b1<sub>2</sub>\u0391\u00b7 In one variation, the second agent is a single compound. However, it is understood that the second agent in one embodiment may be two or more compounds, such as a second agent that comprises a first compound that is a diuretic and a second compound that is an ACE-inhibitor. </p> [0101] In one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u0391\u00b7 In one variation, a compound provided herein exhibits greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or between about 50% and about 90% or between about 60% and about 90% or between about 70% and about 90% or between about 80% and about 100% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist \n\n activity to adrenergic receptor <sub>2</sub>\u0391\u00b7 In one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of <sub>2</sub>A ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>\u0391\u00b7 In one variation, a compound provided herein exhibits greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or between about 50% and about 90% or between about 60% and about 90% or between about 70% and about 90% or between about 80% and about 100% inhibition of <sub>2</sub>A ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>\u0391\u00b7 </p> [0102] In another variation, a compound as provided herein (i) binds to and is an antagonist of adrenergic receptor <sub>2</sub>A and (ii) exhibits greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2 . In one such variation, a compound as provided herein exhibits (i) greater than or equal to about 50% inhibition of <sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A and (ii) greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. When the compound exhibits greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2, in some embodiments, it exhibits greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or between about 50% and about 90% or between about 60% and about 90% or between about 70% and about 90% or between about 80% and about 100% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at \u039f. \u0399\u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. In another variation, a compound as provided herein exhibits (i) greater than or equal to about 50% inhibition of <sub>2</sub>A ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A and (ii) greater than or equal to about 50% inhibition of <sub>2</sub>\u03b2 ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. In another variation, a compound as provided herein exhibits (i) greater than or equal to about 50% inhibition of <sub>2</sub>A ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A and (ii) greater than or equal to about 50% inhibition of <sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. In another variation, a compound as provided herein exhibits (i) greater than or equal to about 50% inhibition of <sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A and (ii) greater than or equal to about 50% inhibition of <sub>2</sub>\u03b2 ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. When the compound exhibits greater than or equal to about 50% inhibition of <sub>2</sub>\u03b2 ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2, in some embodiments, it exhibits greater than or equal to about any one of 50%, \n\n 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or between about 50% and about 90% or between about 60% and about 90% or between about 70% and about 90% or between about 80% and about 100% inhibition of <sub>2</sub>B ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2. It is understood and clearly conveyed herein that an adrenergic receptor <sub>2</sub>A antagonist can exhibit any of the adrenergic receptor <sub>2</sub>A binding profiles described herein in combination with any of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 binding profiles described herein, as if each and every combination were listed separately. </p> [0103] The adrenergic receptor <sub>2</sub>A antagonists may also be used in conjunction with other agents that antagonize the adrenergic receptor \u03b1<sub>2</sub>\u03b2. Administration in conjunction with another compound includes administration in the same or different composition, either sequentially, simultaneously, or continuously. </p> [0104] In one variation, compounds provided herein that bind to and are antagonists of the adrenergic receptor <sub>2</sub>A will also bind to and antagonize the adrenergic receptor ^. In another variation, compounds provided herein that bind to and are antagonists of the adrenergic receptor 2A and either (a) also bind to and are antagonists of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 or (b) are administered in the methods detailed herein in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual, will also bind to and antagonize the adrenergic receptor ^. In some embodiments, compounds provided herein may exhibit greater than or equal to about 50% inhibition of \u00beB ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am. In some embodiments, compounds provided herein may exhibit greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of \u00beB ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u00beB. In some embodiments, compounds provided herein may exhibit greater than or equal to about 50% inhibition of \u00beB ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1^. In some embodiments, compounds provided herein may exhibit greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1^. For example, in one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of <sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic \n\n receptor <sub>2</sub>\u0391 and greater than or equal to about 50% inhibition of ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor ^. In another variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of <sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A, greater than or equal to about 50% inhibition of 2\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2 and greater than or equal to about 50% inhibition of ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am. In one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of <sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor <sub>2</sub>A, greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2 and greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of \u00beB ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1^. It is understood and clearly conveyed herein that an adrenergic receptor 2A antagonist can exhibit any of the adrenergic receptor <sub>2</sub>A binding profiles described herein in combination with any of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 binding profiles described herein, and/or any of the adrenergic receptor \u00beB binding profiles described herein as if each and every combination were listed separately. </p> [0105] The adrenergic receptor <sub>2</sub>A antagonists may also be used in conjunction with other agents that antagonize the adrenergic receptor am. Administration in conjunction with another compound includes administration in the same or different composition, either sequentially, simultaneously, or continuously. </p> [0106] In one variation, compounds provided herein that bind to and are antagonists of the adrenergic receptor <sub>2</sub>A will also bind to and antagonize the adrenergic receptor \u00beD. In another variation, compounds provided herein that bind to and are antagonists of the adrenergic receptor 2A and either (a) also bind to and are antagonists of the adrenergic receptor <sub>2</sub>\u03b2 or (b) are administered in the methods detailed herein in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual, will also bind to and antagonize the adrenergic receptor ^. In another variation, compounds provided herein that bind to and are antagonists of the adrenergic receptor <sub>2</sub>A and either (a) also bind to and are antagonists of the adrenergic receptor <sub>2</sub>\u03b2 or (b) are administered in the methods detailed herein in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual, and \n\n bind to and are antagonists of the adrenergic receptor a will also bind to and antagonize the adrenergic receptor ^. In some embodiments, compounds provided herein may exhibit greater than or equal to about 50% inhibition of m ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u00beD. In some embodiments, compounds provided herein may exhibit greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of m ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am- In some embodiments, compounds provided herein may exhibit greater than or equal to about 50% inhibition of am ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor am- In some embodiments, compounds provided herein may exhibit greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of am ligand binding at 0.03 \u03bc\u039c and antagonist activity to adrenergic receptor am- For example, in one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor a<sub>2</sub>A and greater than or equal to about 50% inhibition of am ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am- In another variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor a<sub>2</sub>A, greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2 and greater than or equal to about 50% inhibition of am ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am- In another variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor a<sub>2</sub>A, greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2, greater than or equal to about 50% inhibition of am ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am, and greater than or equal to about 50% inhibition of am ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor am- In one variation, a compound provided herein exhibits equal to or greater than about 50% inhibition of a<sub>2</sub>A ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor a<sub>2</sub>A, greater than or equal to about 50% inhibition of \u03b1<sub>2</sub>\u03b2 ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor \u03b1<sub>2</sub>\u03b2, greater than or equal to about 50% \n\n inhibition of a ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor a and greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or between about 50% and about 90%, between about 60% and about 90%, between about 70% and about 90%, or between about 80% and about 100% inhibition of m ligand binding at 0.1 \u03bc\u039c and antagonist activity to adrenergic receptor ^. It is understood and clearly conveyed herein that an adrenergic receptor <sub>2</sub>A antagonist can exhibit any of the adrenergic receptor <sub>2</sub>A binding profiles described herein in combination with any of the adrenergic receptor <sub>2</sub>\u03b2 binding profiles described herein, and/or any of the adrenergic receptor \u00beB binding profiles described herein and/or any of the adrenergic receptor \u00beD binding profiles described herein as if each and every combination were listed separately. </p> [0107] The adrenergic receptor <sub>2</sub>A antagonists may also be used in conjunction with other agents that antagonize the adrenergic receptor am. Administration in conjunction with another compound includes administration in the same or different composition, either sequentially, simultaneously, or continuously. </p> [0108] The binding properties to adrenergic receptors of compounds disclosed herein may be assessed by methods known in the art, such as competitive binding assays. In one variation, compounds are assessed by the binding assays detailed herein. In one variation, inhibition of binding of a ligand to a receptor is measured by the assays described herein. In another variation, inhibition of binding of a ligand is measured in an assay known in the art. </p>Functional Assay Profile </p> [0109] Antagonist activity to the adrenergic receptor <sub>2</sub>A, CLIB, OIB <sup>an</sup>d m may be assessed by methods known in the art, such as standard a<sub>2</sub>A, CLIB, OIB <sup>an</sup>d am receptor cell membrane-based or intact cell-based activity assays. For example, the Aequorin-based assay may be used to assess antagonist activity to the adrenergic receptor a<sub>2</sub>A, LIB, OIB or am and the cell membrane- based GTPyS binding assay may be used to assess antagonist activity to the adrenergic receptor \u03b1<sub>2</sub>\u0392\u00b7 </p> [0110] In one variation, adrenergic receptor a<sub>2</sub>A antagonists as provided herein exhibit an IC<sub>50</sub> value equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g. concentration corresponding to ECgo of UK14304 (for Aequorin assay) in an adrenergic receptor a <sub>2</sub>A antagonist assay. \n\n [0111] In another variation, a compound provided herein binds to and is an antagonist of the adrenergic receptor a<sub>2</sub>A, wherein the compound is also an antagonist of the adrenergic receptor 2\u03b2 and exhibits an IC<sub>50</sub> value that is equal to or less than about any one of lOOnM, 30nM or lOnM at a given concentration of agonist (e.g. concentration corresponding to ECgo of oxymetazoline (for Aequorin assay) or guanfacine (for GTPyS assay) in an adrenergic receptor 2\u03b2 antagonist assay. In some embodiments, adrenergic receptor <sub>2</sub>A antagonists as provided herein exhibit: (i) an IC<sub>50</sub> value in an <sub>2</sub>A antagonist assay equal to or less than about any one of lOOnM, 30nM or lOnM at a given concentration of agonist (e.g. concentration corresponding to ECgo of UK14304 (for Aequorin assay), and (ii) an IC<sub>50</sub> value in an <sub>2</sub>\u03b2 antagonist assay that is equal to or less than about any one of lOOnM, 30nM or lOnM at a given concentration of agonist (e.g. concentration correspond",
    "pound binds to and is an inverse agonist of the adrenergic receptor a<sub>2</sub>A and binds to and is antagonist of one or more of the adrenergic receptors \u03b1<sub>2</sub>\u03b2, am and am- In one variation, the compound binds to and is an inverse agonist of the adrenergic receptor a<sub>2</sub>A and binds to and is antagonist of any one of the adrenergic receptors \u03b1<sub>2</sub>\u03b2, a and am- In another variation, the compound binds to and is an inverse agonist of the adrenergic receptor a<sub>2</sub>A and binds to and is antagonist of any two of the adrenergic receptors \u03b1<sub>2</sub>\u03b2, am and am- In yet another variation, the compound binds to and is an inverse agonist of the adrenergic receptor a<sub>2</sub>A and binds to and is antagonist of adrenergic receptors \u03b1<sub>2</sub>\u03b2, a and am- Inverse agonist activity to the adrenergic receptor a<sub>2A</sub>may be assessed by methods known in the art, such as those described in Wade, S.M. et al., Mol. Pharmacol. 59:532-542 (2001). </p> [0119] It is understood and clearly conveyed herein that any of the binding profiles detailed herein can be combined with any of the antagonist profiles detailed herein, as if each and every combination were listed separately. For example, in one variation, a compound provided herein exhibits (i) greater than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 80%, 85%, 90%, 95%, or between about 50% and 90%, between about 60% and about 90%, between about 70% and about 90%, or about 80% and about 100% inhibition of a<sub>2A</sub>ligand binding at \u039f.\u0399\u03bc\u039c to adrenergic receptor a<sub>2A</sub> and an IC<sub>50</sub> value equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g. concentration corresponding to ECgo of UK14304 (for Aequorin assay) in an adrenergic receptor a<sub>2</sub>A antagonist assay; and (ii) greater \n\n than or equal to about any one of 50%, 55%, 60%, 65%, 70%, 80%, 85%, 90%, 95%, or between about 50% and 90%, between about 60% and about 90%, between about 70% and about 90%, or about 80% and about 100% inhibition of <sub>2</sub>B ligand binding at \u039f.\u0399\u03bc\u039c to adrenergic receptor \u03b1<sub>2</sub>\u03b2 and IC<sub>50</sub> value equal to or less than about any one of 100 nM, 30 nM or 10 nM at a given concentration of agonist (e.g. concentration corresponding to ECgo of oxymetazoline (for Aequorin assay) or guanfacine (for GTPyS assay) in an \u03b1<sub>2</sub>\u03b2 antagonist assay. </p>Medical Use </p> [0120] Without being bound by theory, it is believed that compounds that bind to and are antagonists of the adrenergic receptor <sub>2</sub>A affect an increase in insulin secretion and/or promote insulin release into the blood stream in an individual, which aids in glucose uptake. However, such compounds may also increase an individual's blood pressure. When the adrenergic receptor <sub>2</sub>A antagonists as provided herein also bind to and are antagonists of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 and/or the adrenergic receptor \u03b1^, and/or the adrenergic receptor \u03b1^, it is believed that the increases in an individual's blood pressure due to antagonizing the adrenergic receptor 2A may be reduced or eliminated. If an adrenergic receptor <sub>2</sub>A antagonist as provided herein is not also an antagonist of the adrenergic receptor \u03b1<sub>2</sub>\u03b2 and/or the adrenergic receptor \u00beB and/or the adrenergic receptor \u03b1^, then the increase in an individual's blood pressure as a result of the adrenergic receptor <sub>2</sub>A antagonist may be reduced or eliminated by administering the compound in conjunct",
    "reof. Such indications include, but are not limited to type 2 diabetes, glucose intolerance and metabolic syndrome. An individual who has a disease or condition that involves reduced or impaired insulin secretion and/or release may experience one or more beneficial or desirable results upon administration of an adrenergic receptor <sub>2</sub>A antagonist provided herein, or pharmaceutically acceptable salt thereof. In one aspect, the beneficial or desirable result is a reduction in the individual's blood \n\n glucose level for a period of time (e.g., about any one of 6, 12, 24 or 48 hours or more) following administration of the compound or pharmaceutically acceptable salt thereof. In another aspect, the beneficial or desirable result is an increase in glucose metabolism for a period of time (e.g. , about any one of 6, 12, 24 or 48 hours or more) following administration of the compound or pharmaceutically acceptable salt thereof. </p> [0122] Compounds that are inverse agonists of the adrenergic receptor <sub>2</sub>A may stimulate islet cell release of insulin even in the absence of sympathetic stimulation of the adrenergic receptor 2A with epinephrine and/or norepinephrine. Inverse agonists of the adrenergic receptor <sub>2</sub>A provided herein are thus expected to find use in therapy, particularly in indications in which stimulation of islet cell release of insulin would be, or would be expected to be, beneficial. Individuals who have a disease or condition responsive to inhibition of the adrenergic receptor 2A may benefit from the compounds detailed herein, or pharmaceutically acceptable salts thereof. Such indications include, but are not limited to type 2 diabetes, metabolic syndrome, and glucose intolerence. </p> [0123] In one aspect, compounds are provided that do not bind appreciably any one or more of the histamine, dopamine and serotonin receptors. In any of the methods detailed herein, in one variation the individual does not have a cognitive disorder, psychotic disorder, neurotransmitter- mediated disorder and/or neuronal disorder. As used herein, the term \"cognitive disorders\" refers to and intends diseases and conditions that are believed to involve or be associated with or do involve or are associated with progressive loss of structure and/or function of neurons, including death of neurons, and where a central feature of the disorder may be the impairment of cognition (e.g., memory, attention, perception and/or thinking). These disorders include pathogen-induced cognitive dysfunction, e.g. , HIV associated cognitive dysfunction and Lyme disease associated cognitive dysfunction. Examples of cognitive disorders include Alzheimer' s Disease, Huntington's Disease, Parkinson's Disease, schizophrenia, amyotrophic lateral sclerosis (ALS), autism, mild cognitive impairment (MCI), stroke, traumatic brain injury (TBI) and age- associated memory impairment (AAMI). As used herein, the term \"psychotic disorders\" refers to and intends mental d",
    "ndolizino[7,8-b]indole (25 mg). 1H NMR (CD<sub>3</sub>OD, freebase) \u03b4 (ppm): 7.32 (m, 3H), 7.26 (s, 1H), 7.13 (m, 2H), 7.09 (d, 1H), 5.09 (t, 1H), 4.8 (m, 1H), 4.32 (m, 2H), 3.44 (m, 2H), 3.3 (m, 1H), 3.1 (m, 1H), 3.0 (d, 1H), 2.8 (m, 1H), 2.6 (m, 1H), 2.4 (s, 3H), 2.18 (m, 2H), 2.0 (m, 1H). Separation by chiral HPLC provides diastereomers V-23a-d. </p> Example 423. </p> [1072] Compounds 11-266 to 11\u2014269 and 11-271 to 11-299 can be synthesized in an analogous fashion to other compounds described herein and by reference to the PCT publications listed in the General Methods above. </p>Example B 1 : Determination of the ability of compounds of the invention to bind an adrenergic receptor. </p> Adrenergic OC?R </p>[1073] To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic &lt;\u00beB receptor expressed in Chinese hamster ovary (CHO) Kl cells (Uhlen, S. et al, Eur. J. Pharmacol. 343(1):93, 1998) in a modified Tris-HCl buffer (50 mM Tris- HCl, pH 7.4, 12.5 mM MgC12, 1 mM EDTA, 0.2% BSA) was used. Compounds of the invention were incubated with 2.5 nM [3H]Rauwolscine for 60 min at 25 \u00b0C. Non-specific binding was estimated in the presence of 10 \u03bc\u039c Prazosin. Receptor proteins were filtered and \n\n washed, the filters were then counted to determine [3H]Rauwolscine specifically bound. </p>Compounds were screened at 1 \u03bc\u039c or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table Bl. </p>Adrenergic (\u03a7?\u0391 </p> [1074] To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic &lt;\u00beA receptor expressed in insect Sf9 cells (Uhlen, S. et al, J. Pharmacol. Exp. Ther. 271: 1558, 1994) in a modified Tris-HCl buffer (50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl<sub>2</sub>, 2 mM EDTA) was used. Compounds of invention were incubated with 1 nM [<sup>3</sup>H]MK-912 for 60 min at 25 \u00b0C. MK912 is (2S-trans)-l,3,4,5',6,6',7,12b-octahydro-r,3'- dimethyl-spiro[2H-benzofuro[2,3-a]quinolizine-2,4'( H)-pyrimidin]-2'(3'H)-one hydrochloride. Non-specific binding was estimated in the presence of 10 \u03bc\u039c WB-4101 (2-(2,6- Dimethoxyphenoxyethyl)aminomethyl- 1 ,4-benzodioxane hydrochloride) . Receptor proteins were filtered and washed, the filters were then counted to determine [ H]MK-912 specifically bound. Compounds were screened at 1 \u03bc\u039c or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table B 1. </p>Adrenergic ocm </p> [1075] To evaluate in radioligand binding assays the activity of compounds of the invention, rat adrenergic &lt;\u00beB receptor obtained from Wistar Rat liver (Garcia-S'ainz, J. et al, Biochem. Biophys. Res. Commun. 186:760, 1992; Michel, A. et al, Br. J. Pharmacol. 98:883, 1989) in a modified Tris-HCl buffer (50 mM Tris-HCl buffer, pH 7.4, 0.5 mM EDTA) was used. </p>Compounds of the invention were incubated with 0.25 nM [ H]Prazosin for 60 min at 25 \u00b0C. Non-specific binding was estimated in the presence of 10 \u03bc\u039c phentolamine. Receptor proteins were filtered and washed, the filters were then counted to determine [ H]Prazosin specifically bound. Compounds were screened at 1 \u03bc\u039c or lower, using 1% DMSO as vehicle. Compounds of the invention were tested in this biochemical assay and percent inhibition of specific binding \n\n was determined. Biochemical assay results are presented as the percent inhibition of specific binding in Table B 1. </p>Adrenergic ocm </p> [1076] To evaluate in radioligand binding assays the activity of compounds of the invention, human recombinant adrenergic am receptor expressed in human embryonic kidney (HEK-293) cells (Kenny, B. et al, Br. J. Pharmacol. 115(6):981, 1995) in a 50 mM Tris-HCl buffer, pH 7.4, was used. Compounds were incubated with 0.6 nM [ H]Prazosin for 60 min at 25 \u00b0C. Nonspecific binding was estimated in the presence of 10 \u03bc\u039c phentolamine. Receptor proteins were filtered and washed, the filters were then counted to determine [ H]Prazosin specifically bound. Compounds were screened at 1 \u03bc\u039c or lower, using 1% DMSO as vehicle. Biochemical assay results are presented as the percent inhibition of specific binding in Table B 1. </p> Table B 1 : Percentage inhibition of ligand binding to aminergic G protein-coupled receptors by compounds of the invention: </p><img id=\"imgf000449_0001\" path=\"imgf000449_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/211929639/WO/20121115/A1/002012/15/42/61/imgf000449_0001.tif\"/>\nCompound Adrenergic (0.1 \u03bc\u039c)* Adrenergic (0.03 \u03bc\u039c)* No. \u03b1<sub>1\u0392</sub> a<sub>1D</sub> a<sub>1B</sub> a<sub>1D</sub> </p> 9b 10 - 10 - - - - 50</p>10a 30 - 8 - - - - 34</p>10b 28 - 15 - - - - 91</p>11a 16 - -6 - - - - 28 lib 18 - 13 - - - - 64</p>12a 23 - 3 - - - - 24</p>12b 8 - 3 - - - - 21</p>13 83 - 18 - - - - 92</p>13a 75 - -2 - - - - 37</p>13b 91 - -2,21 - 68 - - 100,102</p>14a 43,44 - 8,26 - 17 - - 97,98</p>14b 25 - -6 - - - - 14</p>15 93 - 19 - - - - 93</p>15a 81 - 6 - - - - 65</p>15b 89,93 - 21,24 - 73 - - 103</p>16a 47 - 9 - - - - 33</p>16b 16 - 2 - - - - 2</p>17 18 - 19 - - - - 37</p>17a 13 - 19 - - - - 32</p>17b 16 - 9 - - - - 20</p>18a 55 - 50 - - - - 54</p>18b 87 - 32 - - - - 61</p>19a 75 - 21 - - - - 75</p>19b 62 - 9 - - - - 27</p>20a 67 - 29 - - - - 28</p>20b 94 - 28 - - - - 36</p>21a 5 - -1 - - - - -2</p>21b -2 - -3 - - - - 1</p>22a 19 - 16 - - - - 22</p>22b 9 - 0 - - - - 30</p>23a -20 - 4 - - - - 6</p>23b 4 - 1 - - - - -3</p>24a 8 - 8 - - - - 63</p>24b 8 - 15 - - - - 29</p>25a 4 - 15 - - - - 54</p>25b 12 - 18 - - - - 75</p>26a 52,61 - 23,33 - 32 - 14 101,107</p>26b 15 - 12 100 - - - 75,88</p>26c 1 - 19 - - - - 1,7</p>26d -2 - 0 - - - - 6,11 \n\n Compound Adrenergic (0.1 \u03bc\u039c)* Adrenergic (0.03 \u03bc\u039c",
    "- - 53</p>11-241 5 - -1 - - - - -1</p>11-242 4 - 2 - - - - 3</p>11-243 91,93 - 19 82 79 - - 58,61</p>II-244a 95 - 22 - - - - 102</p>II-244b 12 - 2 - - - - 16</p>11-245 27 - 7 - - - - 44</p>11-246 -2 - 47 - - - - 5</p>11-247 3 - 83 - - - - 19</p>11-248 4 - 88 - - - - 5</p>11-249 6 - 74 - - - - 4</p>11-250 -5 - 57 - - - - 6</p>11-251 -7 - 81 - - - - -4</p>11-252 -1 - 91 - - - - 1</p>11-253 9 - 54 - - - - 16</p>11-261 71 - 70 - - - - 103</p>11-262 3 - 10 - - - - 11</p>11-263 2 - 10 - - - - 10</p>IV-2 - - - 50 - - - -</p>IV-4 2 15 -3 56 - - - -</p>IV-8a 49 - 7 - - - - 4</p>IV-8b 5 - 22 - - - - 3</p>IV-93a 7 - 18 - - - - 52</p>IV-93b 65 - -1 - - - - 44</p>IV-209a 89 - 6 - - - - 72</p>IV-209b 11 - 10 - - - - 13</p>IV-209c 98 - 59 - - - - 102</p>IV-209d 54 - 8 - - - - 79</p>IV-210a 70,75 - 37 - 43 - - 101,103</p>IV-210b 10 - 8 - - - - 29</p>IV-210c -4 - 1 - - - - 10</p>IV-210d 19 - 13 - - - - 87</p>V-l 15 - 35 - - - - 102 \n\n Compound Adrenergic (0.1 \u03bc\u039c)* Adrenergic (0.03 \u03bc\u039c)* No. \u03b1<sub>1\u0392</sub> a<sub>1D</sub> a<sub>1B</sub> a<sub>1D</sub> </p> V-la 20 - 36 - - - - 88</p>V-lb 57 - 29 - - - - 102</p>V-2 49 - 2 - - - - 61</p>V-3 22 - 40 - - - - 71</p>V-14a 0 - 18 - - - - 7</p>V-14b 2 - 3 - - - - 0</p>V-15 4 - 7 - - - - 20</p>V-18a 78 - 13 - - - - 57</p>V-18b 95 - 57 - - - - 98</p>V-2 la 68 - 62 - - - - 98</p>V-21b 34 - 43 - - - - 93</p>V-22 28 - 18 - - - - 90</p>V-23 94 - 109 - - - - 105</p>Where shown, some compounds were tested in repeat assays, each datapoint is shown.</p>Table B2: Ki values of compounds of the invention*: </p><img id=\"imgf000467_0001\" path=\"imgf000467_0001.tif\" file=\"https://surechembl.org/api/assets/attachment/211929665/WO/20121115/A1/002012/15/42/61/imgf000467_0001.tif\"/>\n Compound No. a<sub>2B</sub> (nM) a<sub>2A</sub> (nM) a<sub>1B</sub> (nM) a<sub>1D</sub> (nM)</p>120 20.52 65.83 - -</p>127a 15.14 - - -</p>128a 0.97 98.62 - -</p>129c 0.77 88.55 - -</p>129d 0.35 1.87 - -</p>130a 1.66 6.91 - -</p>130b 2.52 72.60 - -</p>131b 7.95 - - -</p>133b 2.42 59.45 - -</p>134b 0.43 102 - -</p>139a 2.36 - - -</p>139 8.12 390 - -</p>141b 3.44 - - -</p>144b 1.70, 2.36 - - -</p>148b 0.43 - - -</p>147 1.49 - - -</p>150a 1.57 - - -</p>154b 3.33 - - -</p>173a 8.77 - - -</p>174a 7.91 - - -</p>175a 4.42 - - -</p>176a 0.53 - - -</p>183b - 2.72 - -</p>184 - 184 - -</p>185 3.80 20.97 - -</p>186 0.52 11.04 - -</p>187 4.43 17.89 - -</p>189 0.86 2.86 - -</p>190 2.26 12.83 - -</p>191 3.23 2.10 - -</p>196a 1.83 16.80 - -</p>197b 0.78 11.90 - -</p>200 - 1.63, 3.21 - -</p>204 - 2.48 - -</p>206 - 1.12, 6.79 - -</p>207 - 1.16 - -</p>213 26.30 - - -</p>214 12.91 22.67 - -</p>216 0.95 9.59 - -</p>243 - 3.86 - -</p>325 206 9.88 - -</p>II- 16b 5.58 - - -</p>11-82 26.76 - - -</p>11-105 152 - - - \n\n Compound No. a<sub>2B</sub> (nM) a<sub>2A</sub> (nM) a<sub>1B</sub> (nM) a<sub>1D</sub> (nM)</p>II-121a - 4.52 - -</p>II- 121b 0.22 9.18 - -</p>II- 125b 0.16 1.21 - -</p>II- 128b 0.49 13.07 - -</p>II- 135b 0.53 - - -</p>11-243 9.44 - - -</p>IV-210a 0.33 - - -</p>V-l 0.51 - - ",
    "ntion. The i reference agonist and antagonist were cirazoline and qinazoline, respectively. The a<sub>2A</sub> \n\n reference agonist and antagonist were UK14,304 and rauwolscine, respectively. The \u03b1<sub>2</sub>\u03b2 reference agonist and antagonist were oxymetazoline and rauwolscine, respectively. </p>[1080] For agonist testing, 50 \u03bc\u0390<sub>^</sub> of cell suspension were injected on 50\u03bc\u03af of test compound or reference agonist plated in a 96-well plate. The resulting emission of light was recorded using the Hamamatsu Functional Drug Screening System 6000 (FDSS 6000). For antagonist testing, following an incubation of 15 min. after the first injection, 100 \u03bc\u0390<sub>^</sub> of reference agonist at a concentration corresponding to its ECso was injected on the 100 \u03bc\u0390<sub>^</sub> of the mixture of cell suspension and test compound. The resulting emission of light was recorded using the same luminometer as for agonist testing. To standardize the emission of recorded light (determination of the \"100% signal\") across plates and across different experiments, some of the wells contained 100 \u03bc\u039c digitonin or a saturating concentration of ATP (20 \u03bc\u039c). Plates also contained the reference agonist at a concentration equivalent to the ECso obtained during the test validation. </p> [1081] Agonist activity of test compound was expressed as a percentage of the activity of the reference agonist at its EC<sub>10</sub>o concentration. Antagonist activity of test compound was expressed as a percentage of the inhibition of reference agonist activity at its ECso concentration. </p>[1082] Compounds were tested for agonist &amp; antagonist activity at the human adrenergic \u00beB (FAST-008A), adrenergic cc<sub>2A</sub> (FAST-006A) or adrenergic cc<sub>2B</sub> (FAST-007A) at the following nanomolar concentrations, in duplicate: Agonist (nM): 0.3, 1, 3, 10, 30, 100, 300, 1000, 3000, 10000; Antagonist (nM): 0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500, 5000. </p>[1083] GTPyS Assay Procedure: The procedure was carried out with the following: assay buffer [20mM HEPES pH 7.4; lOOmM NaCl, 10 \u03bcg/mL saponin, ImM MgCl<sub>2</sub>] ; membranes [Recombinant CHO-K1 -adrenergic &lt;\u00beB membrane extracts thawed on ice and diluted in assay buffer to give 10 \u03bcg /well and kept on ice] ; GDP [diluted in assay buffer to give 3 \u03bc\u039c final concentration] ; beads [PVT-WGA (Amersham, RPNQ0001), diluted in assay buffer at </p>0.5mg/well] ; GTPy<sup>35</sup>S [(PerkinElmer NEG030X), diluted in assay buffer to give 0.1 nM final concentration] ; ligand [Guanfacine (Tocris, 1030) as reference agonist and Rauwolscine (Tocris, 891) as reference antagonist, diluted in assay buffer] . Membranes were mixed with GDP</p> TPyr 35 </p> (volume: volume) and incubated for at least 15 min. on ice. In parallel, G S] was mixed with the beads (volume:volume) just before starting the reaction. \n\n [1084] For agonist testing, the following reagents were successively added in the wells of an Optiplate (Perkin Elmer): 50 \u03bc\u0390<sub>^</sub> of te"
]